Ligand PharmaceuticalsLGND
About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Employees: 68
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
16% more call options, than puts
Call options by funds: $999K | Put options by funds: $860K
12% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 86
10% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 29
0% more capital invested
Capital invested by funds: $1.95B [Q4 2024] → $1.96B (+$3.5M) [Q1 2025]
0.05% more ownership
Funds ownership: 96.43% [Q4 2024] → 96.48% (+0.05%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% less funds holding
Funds holding: 254 [Q4 2024] → 253 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Oppenheimer Trevor Allred | 38%upside $145 | Outperform Maintained | 9 May 2025 |
Stifel Annabel Samimy | 36%upside $143 | Buy Initiated | 10 Apr 2025 |
Financial journalist opinion
Based on 5 articles about LGND published over the past 30 days









